8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 8, 2010

MedQuist Inc.

(Exact name of registrant as specified in charter)

New Jersey	001-13326	22-2531298
(State of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)

1000 Bishops Gate Boulevard, Suite 300,
Mount Laurel, New Jersey 08054-4632
(Address of principal executive offices) (Zip Code)

(856) 206-4000
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On October 8, 2010, the Company issued a press release announcing the Company currently expects that the payment date for the special cash dividend will be October 15, 2010 and that the Company anticipates the ex-dividend date will be the first business day following the dividend payment date. The Company noted, however, that no assurance could be given by the Company that this would be the case as the determination of the ex-dividend date would be made by NASDAQ upon notification that the conditions to the payment of the dividend have been satisfied.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference into this Item 8.01.

Item 9.01. Financial Statements and Exhibits.

          (d) Exhibits.

Exhibit Number	Description of Exhibit
99.1	Press Release issued by the Company, dated October 8, 2010.

Signatures

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MedQuist Inc.
Date: October 12, 2010	By:	/s/ Mark Sullivan
		Mark Sullivan
		General Counsel, Chief Compliance Officer & Secretary

     Exhibit Index

Exhibit Number	Description of Exhibit
99.1	Press Release issued by the Company, dated October 8, 2010.

EX-99.1

Exhibit 99.1

MEDQUIST PROVIDES UPDATE ON SPECIAL DIVIDEND TIMING

MOUNT LAUREL, N.J. October 8, 2010 — MedQuist Inc. (Nasdaq: MEDQ), a leading provider of integrated clinical documentation solutions for the U.S. healthcare industry, has previously announced that in connection with entering into definitive agreements relating to a $310 million financing consisting of a $225 million senior secured credit facility and the issuance of $85 million of senior subordinated notes, the Board of Directors of MedQuist has declared a special cash dividend of $4.70 per share to all MedQuist shareholders of record as of October 11, 2010. The closing of the financing and the payment of the special cash dividend are conditioned upon the satisfaction of customary closing conditions under the financing agreements. MedQuist currently expects that the payment date for the special cash dividend will be October 15, 2010. Under NASDAQ rules applicable to cash dividends which are 25% or greater of the value of the subject security, MedQuist anticipates that the ex-dividend date will be the first business day following the dividend payment date, but no assurance can be given by MedQuist that this will be the case and the determination of the ex-dividend date will be made by NASDAQ upon notification that the conditions to the payment of the dividend have been satisfied.

Statements made in this press release that are forward-looking in nature are intended to be “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934 and may involve risk and uncertainties. These statements include, without limitation, statements regarding the terms of the transactions described herein and any other statements that are not historical facts. These risks and uncertainties include the timing and satisfaction of conditions for the proposed transactions. Other risks and uncertainties relating to our business and our financial condition are more fully described in documents filed by MedQuist with the SEC, including Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

# # #

Contacts:

MedQuist Investor Relations
Phone: 856-206-4567